HNSCC Phase I/II clinical trial (QBC46-H03) completes patient recruitment

2 March 2022

The Phase I/II clinical trial (QBC46-H03) evaluating the optimal dose of our lead oncology molecule tigilanol tiglate in patients with head and neck squamous cell carcinoma (HNSCC) has completed patient recruitment.  The study is currently in the close-out phase prior to final reporting.